DK2126049T3 - Antistoffer mod humant cytomegalovirus (hCMV) - Google Patents

Antistoffer mod humant cytomegalovirus (hCMV)

Info

Publication number
DK2126049T3
DK2126049T3 DK07857724.4T DK07857724T DK2126049T3 DK 2126049 T3 DK2126049 T3 DK 2126049T3 DK 07857724 T DK07857724 T DK 07857724T DK 2126049 T3 DK2126049 T3 DK 2126049T3
Authority
DK
Denmark
Prior art keywords
hcmv
human cytomegalovirus
antibodies
infections
sequences
Prior art date
Application number
DK07857724.4T
Other languages
English (en)
Inventor
Ada Funaro
Giorgio Gribaudo
Santo Landolfo
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2006/069780 external-priority patent/WO2007068758A1/en
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Application granted granted Critical
Publication of DK2126049T3 publication Critical patent/DK2126049T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK07857724.4T 2006-12-15 2007-12-17 Antistoffer mod humant cytomegalovirus (hCMV) DK2126049T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2006/069780 WO2007068758A1 (en) 2005-12-16 2006-12-15 Methods for obtaining immortalized antibody secreting cells
EP07110693 2007-06-20
PCT/EP2007/064094 WO2008071806A1 (en) 2006-12-15 2007-12-17 Antibodies against human cytomegalovirus (hcmv)

Publications (1)

Publication Number Publication Date
DK2126049T3 true DK2126049T3 (da) 2011-07-18

Family

ID=40935039

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07857724.4T DK2126049T3 (da) 2006-12-15 2007-12-17 Antistoffer mod humant cytomegalovirus (hCMV)

Country Status (18)

Country Link
US (1) US8153129B2 (da)
EP (1) EP2126049B1 (da)
JP (1) JP5351041B2 (da)
KR (1) KR20090114364A (da)
CN (1) CN101627115B (da)
AT (1) ATE503769T1 (da)
AU (1) AU2007331463B2 (da)
BR (1) BRPI0720464A2 (da)
CA (1) CA2672703C (da)
DE (1) DE602007013618D1 (da)
DK (1) DK2126049T3 (da)
EA (1) EA018701B1 (da)
ES (1) ES2363992T3 (da)
IL (1) IL199366A (da)
NO (1) NO20092671L (da)
PL (1) PL2126049T3 (da)
PT (1) PT2126049E (da)
WO (1) WO2008071806A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EP2190876A1 (en) * 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antibodies against human cytomegalovirus (hcmv)
PT3009449T (pt) 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes
US8703486B2 (en) * 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
MX2013002960A (es) * 2010-09-29 2013-05-09 Genentech Inc Composiciones de anticuerpo y metodos de uso.
WO2013148373A1 (en) 2012-03-28 2013-10-03 Genentech, Inc. Anti-hcmv idiotypic antibodies and uses thereof
KR101581158B1 (ko) 2014-03-26 2015-12-30 울산대학교 산학협력단 거대세포바이러스 실제 감염 여부를 진단하기 위한 거대세포바이러스의 감염 해석 모델
HRP20201468T1 (hr) * 2014-05-19 2020-12-11 F. Hoffmann - La Roche Ag Postupak za proizvodnju polipeptida
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN112898414B (zh) * 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1445243A (zh) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 抗人巨细胞病毒人源中和性基因工程Fab抗体
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders

Also Published As

Publication number Publication date
AU2007331463B2 (en) 2014-03-27
BRPI0720464A2 (pt) 2014-01-14
EP2126049A1 (en) 2009-12-02
US20100040602A1 (en) 2010-02-18
CN101627115B (zh) 2013-05-29
NO20092671L (no) 2009-09-03
JP5351041B2 (ja) 2013-11-27
AU2007331463A1 (en) 2008-06-19
CA2672703A1 (en) 2008-06-19
PT2126049E (pt) 2011-07-04
EP2126049B1 (en) 2011-03-30
US8153129B2 (en) 2012-04-10
DE602007013618D1 (de) 2011-05-12
CA2672703C (en) 2016-11-22
IL199366A (en) 2015-03-31
CN101627115A (zh) 2010-01-13
EA018701B1 (ru) 2013-10-30
JP2010512736A (ja) 2010-04-30
PL2126049T3 (pl) 2011-09-30
ES2363992T3 (es) 2011-08-22
ATE503769T1 (de) 2011-04-15
KR20090114364A (ko) 2009-11-03
EA200970586A1 (ru) 2009-12-30
WO2008071806A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
PT2126049E (pt) Anticorpos contra citomegalovírus humano (hcmv)
EA201000424A1 (ru) Антитела к il-23
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
UA109658C2 (xx) Антитіло проти cgrp
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
EA201001212A1 (ru) Лечение микробных инфекций
PH12012501308A1 (en) Binding members for human cytomegalovirus
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
EA200970529A1 (ru) Антивирусная композиция и способ ее применения
EP2555798A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSIONS
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
MX341020B (es) Peptidos derivados de lactoferrina humana y su uso.